Last reviewed 2026-05-15 · How we verify

ChimeriVax-WN02 vaccine

Sanofi Pasteur, a Sanofi Company · Phase 2 active Biologic

ChimeriVax-WN02 vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development for Prevention of West Nile virus infection.

ChimeriVax-WN02 vaccine works by inducing an immune response against the West Nile virus.

ChimeriVax-WN02 vaccine works by inducing an immune response against the West Nile virus. Used for Prevention of West Nile virus infection.

At a glance

Generic name	ChimeriVax-WN02 vaccine
Sponsor	Sanofi Pasteur, a Sanofi Company
Modality	Biologic
Therapeutic area	Infectious Diseases
Phase	Phase 2

Mechanism of action

This vaccine uses a recombinant DNA technology to produce a virus-like particle that stimulates the body's immune system to produce antibodies against the West Nile virus. This immune response helps to protect against future infections.

Approved indications

Prevention of West Nile virus infection

Common side effects

Pain, redness, or swelling at the injection site

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ChimeriVax-WN02 vaccine CI brief — competitive landscape report
ChimeriVax-WN02 vaccine updates RSS · CI watch RSS
Sanofi Pasteur, a Sanofi Company portfolio CI

Frequently asked questions about ChimeriVax-WN02 vaccine

What is ChimeriVax-WN02 vaccine?

ChimeriVax-WN02 vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Prevention of West Nile virus infection.

How does ChimeriVax-WN02 vaccine work?

ChimeriVax-WN02 vaccine works by inducing an immune response against the West Nile virus.

What is ChimeriVax-WN02 vaccine used for?

ChimeriVax-WN02 vaccine is indicated for Prevention of West Nile virus infection.

Who makes ChimeriVax-WN02 vaccine?

ChimeriVax-WN02 vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

What development phase is ChimeriVax-WN02 vaccine in?

ChimeriVax-WN02 vaccine is in Phase 2.

What are the side effects of ChimeriVax-WN02 vaccine?

Common side effects of ChimeriVax-WN02 vaccine include Pain, redness, or swelling at the injection site.

Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
Therapeutic area: All drugs in Infectious Diseases
Indication: Drugs for Prevention of West Nile virus infection